Pulmonary toxicities from targeted therapies: A review

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 235-243

  Barber, Nicholas A ^a   Ganti, Apar Kishor ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Dasatinib; Erlotinib; Gefitinib; Interstitial pneumonitis; mTOR inhibitors; Non specific acute interstitial lung disease; Pulmonary toxicity; Targeted therapy

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BCR ABL PROTEIN INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NILOTINIB; OFATUMUMAB; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANOREXIA; ASTROCYTOMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; BREAST CANCER; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COLORECTAL CANCER; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOXIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLITIS; LUNG EMBOLISM; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RESPIRATORY DISTRESS; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; STOMATITIS;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG DISEASES; MOLECULAR TARGETED THERAPY;

EID: 84856058201     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0199-0     Document Type: Review

References (86)

1. Cohen MH, Williams GA et al (2003) FDA drug approval summary: gefitinib (ZD 1839) (Iressa® ) tablets. Oncologist 8:303-306 (Pubitemid 36929716)
2. Cohen MH et al (2005) FDA drug approval summary: erlotinib (Tarceva® ) tablets. Oncologist 10:461-466 (Pubitemid 41266326)
3. O'Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004 (Pubitemid 36302244)
4. Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417 (Pubitemid 44903745)
5. Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270
6. Saglio G et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259
7. Cutsem EV et al (2009) Cetuximab and chemotherapy as initial treatment for colorectal cancer. N Eng J Med 360:1408-1417
8. Cutsem EV et al (2007) Open-labeled phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
9. Motzer R et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
10. Motzer R et al (2010) Phase III trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256-4265
11. Fukuoka M, Yano S et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246 (Pubitemid 46621858)
12. Kris MG, Natale RB et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158 (Pubitemid 37432975)
13. Mok TS, Wu YL et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
14. Maemondo M, Inoue A et al (2010) Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388
15. Cohen MH et al (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 8:303-306 (Pubitemid 36929716)
16. Ando M, Okamoto I et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556 (Pubitemid 46630633)
17. Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 (Pubitemid 38720929)
18. Inoue A et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139 (Pubitemid 36092019)
19. Dimopoulou I et al (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Onc 17:372-379 (Pubitemid 43329572)
20. Danson S et al (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28:103-113 (Pubitemid 40321766)
21. Suzuki M et al (2008) Recurrent gefitinib-induced interstitial lung disease. Intern Med 47:533-536 (Pubitemid 351663670)
22. Herbst RS et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
23. Gatzemeier U et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545-1552 (Pubitemid 46733081)
24. Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
25. Liu V et al (2007) Pulmonary toxicity associated with erlotinib. Chest 132:1042-1044
26. Makris D et al (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7:150
27. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743 (Pubitemid 46021510)
28. Bokemeyer C et al (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
29. Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 359:1116-1127
30. Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601-609
31. Chua W et al (2009) Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 8:118-120
32. Giusti RM et al (2008) U.S. Food and drug administration approval: panitumumab for epidermal growth factor receptor - expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14:1296-1302 (Pubitemid 351413907)
33. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
34. Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
35. DeMatteo RP et al (2009) Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet 373:1097-1104
36. Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 (Pubitemid 34879334)
37. Quintás-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914 (Pubitemid 47477268)
38. Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143-5150 (Pubitemid 46890528)
39. Stephens J et al (2010) The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 3:31-36
40. Rajda J, Phatak PD (2005) Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Amer J Hem 79:80-81 (Pubitemid 40604802)
41. Yamasawa H et al (2008) Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 75:350-354 (Pubitemid 351450409)
42. Isshiki I et al (2004) Interstitial pneumonitis during imatinib therapy. Brit J Haemat 125:420 (Pubitemid 38916187)
43. Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Res Crit Care Med 176:814-818 (Pubitemid 47598483)
44. Kaelin W (2004) The von hippel-lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S-6295S
45. Pham P et al (2004) Sirolimus-associated pulmonary toxicity. Clin Transplant 77:1215-1220 (Pubitemid 38580300)
46. Miwa Y et al (2008) Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumat 18:208-211
47. Vandewiele B et al (2010) Diffuse alveolar hemorrhage induced by everolimus. Chest 137:456-459
48. White D et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Res Crit Care Med 182:396-403
49. Porta C, et al. (2009) Recommendations for adverse event management in patients with renal cell carcinoma treated with everolimus: safety data from the RECORD-1 Trial: Poster Presented at the 8th International Kidney Cancer Symposium, Chicago, IL, September 25-26, 2009
50. Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 356:2271-2281 (Pubitemid 46849157)
51. Bellmunt J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Onc 19:1387-1392
52. Maroto JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Onc. doi:10.1200/JCO.2010.29.2235
53. Duran I et al (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Euro J Cancer 42:1875-1880 (Pubitemid 44149096)
54. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335-2342 (Pubitemid 38702844)
55. Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for Non-small-cell lung cancer. N Eng J Med 355:2542-2550 (Pubitemid 44917502)
56. Rini B et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Onc 26:5422-5428
57. Johnson D et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Onc 22:2184-2191 (Pubitemid 41095154)
58. Myung HJ et al (2010) Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut and Liver 4:543-546
59. Seidel C et al (2010) Recall pneumonitis during systemic treatment with sunitinib. Ann Oncol 21(10):2119-2120
60. Leon RJ et al (1994) Rituximab-induced acute pulmonary fibrosis: letters to the editor. Mayo Clin Proc 79:949-950
61. Burton C et al (2003) Interstitial pneumonitis related to rituximab therapy: to the editor. N Eng J Med 348:2690-2691 (Pubitemid 36741603)
62. Kim KM et al (2008) Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 49:155-158 (Pubitemid 351513659)
63. Herishanu Y et al (2006) Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 6:407-409
64. Lim KH et al (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25:86-92
65. Swords R et al (2004) Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Amer J Hem 77:103-104 (Pubitemid 39108808)
66. Kishi J et al (2009) A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 48:447-448
67. Lioté H et al (2010) Rituximab-induced lung disease: a systematic literature review. Eur Respir J 35:681-687
68. Ofatumumab CBD (2010) A novel anti-CD20 monoclonal antibody for the treatement of B-cell malignancies. J Clin Oncol 28:1-6
69. Osterborg A et al (2008) Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 112:126-127
70. Coiffier B et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111:1094-1100 (Pubitemid 351213387)
71. Keating MJ et al (2002) Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554-3561 (Pubitemid 34534522)
72. Lozanski G et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281 (Pubitemid 38525651)
73. Sachdeva A, Matuschak GM (2008) Diffuse alveolar hemorrhage following alemtuzumab. Chest 133:1476-1478 (Pubitemid 351893006)
74. San Miguel JF et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917
75. Goy A, et al. (2006) Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement):7512
76. Miyakoshi S et al (2006) Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107:3492-3494
77. Zappasodi P et al (2007) Rapid response to high-dose steroids of severe bortezomib-related pulmonary complications in multiple myeloma. J Clin Oncol 25:3380-3381 (Pubitemid 47325628)
78. Rajkumar SV et al (2005) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative group. J Clin Oncol 24:431-436
79. Rajkumar SC et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053
80. List A et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465 (Pubitemid 44511560)
81. Bennett CL et al (2006) Thalidomide and lenalidomide-associated thromboembolism among patients with cancer. JAMA296:2558-2560 (Pubitemid 44903859)
82. Onozawa M, et al. (2005) Thalidomide-induced interstitial pneumonitis. J Clin Oncol 2425-2426
83. Sasaki M et al (2008) Thalidomide may induce interstitial pneumonia preferentially in Japanese patients. Euro J Haem 82:73-74
84. Feaver AA et al (2006) Thalidomide-induced organizing pneumonia. So Med J 99:1292-1294 (Pubitemid 44875859)
85. Tilluckdharry L et al (2008) Thalidomide-related eosinophilic pneumonia: a case report and brief literature review. Cases Journal 1:1-4
86. Chen C et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Brit J Haemat 146:164-170